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Stu¨ve-Wiedemann syndrome (SWS) is a severe autosomal recessive condition characterized by bowing of the long
bones, with cortical thickening, ﬂared metaphyses with coarsened trabecular pattern, camptodactyly, respiratory
distress, feeding difﬁculties, and hyperthermic episodes responsible for early lethality. Clinical overlapwith Schwartz-
Jampel type 2 syndrome (SJS2) has suggested that SWS and SJS2 could be allelic disorders. Through studying a
series of 19 families with SWS/SJS2, we have mapped the disease gene to chromosome 5p13.1 at locus D5S418
( at ) and have identiﬁed null mutations in the leukemia inhibitory factor receptor (LIFR orZ p 10.66 vp 0max
gp190 chain) gene. A total of 14 distinct mutations were identiﬁed in the 19 families. An identical frameshift
insertion (653_654insT) was identiﬁed in families from the United Arab Emirates, suggesting a founder effect in
that region. It is interesting that 12/14 mutations predicted premature termination of translation. Functional studies
indicated that these mutations alter the stability of LIFR messenger RNA transcripts, resulting in the absence of
the LIFR protein and in the impairment of the JAK/STAT3 signaling pathway in patient cells.We conclude, therefore,
that SWS and SJS2 represent a single clinically and genetically homogeneous condition due to null mutations in
the LIFR gene on chromosome 5p13.
Introduction
Stu¨ve-Wiedemann syndrome (SWS [MIM 601559]) be-
longs to the group of the bent-bone dysplasias and is
characterized by bowing of the lower limbs, with internal
cortical thickening, wide metaphyses with abnormal tra-
becular pattern, and camptodactyly (Stu¨ve and Wiede-
mann 1971; Cormier-Daire et al. 1998). Additional fea-
tures include feeding and swallowing difﬁculties, as well
as respiratory distress and hyperthermic episodes, which
cause death in the ﬁrst months of life. The rare survivors
develop progressive scoliosis; spontaneous fractures;bow-
ing of the lower limbs, with prominent joints and dysau-
tonomia symptoms, including temperature instability; ab-
sent corneal and patellar reﬂexes; and smooth tongue
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(Kozlowski and Tenconi 1996; Superti-Furga et al. 1998;
Chen et al. 2001; Al-Gazali et al. 2003; Di Rocco et al.
2003). Clinical and radiological overlap with Schwartz-
Jampel type 2 syndrome (SJS2) has suggested that SWS
and SJS2 could be a single entity (Al-Gazali et al. 1996;
Cormier-Daire et al. 1998; Superti-Furga et al. 1998).
Here, we report the mapping of the SWS/SJS2 gene on
chromosome 5p13.1 and the identiﬁcation of null mu-
tations in the leukemia inhibitory factor receptor (LIFR
[GenBank accession number NM_002310]) gene in 19
affected families. It appears, therefore, that SWS and SJS2
represent a single clinically and genetically homogeneous
condition.
Material and Methods
Patients
A total of 24 children from 19 families (14 consan-
guineous and 5 nonconsanguineous families) were in-
cluded in the study. Among them, 10 have been reported
elsewhere (Al-Gazali et al. 1996, 2003; Chabrol et al.
1997; Cormier-Daire et al. 1998; Superti-Furga et al.
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Table 1
Two-Point LOD Scores for Linkage of an SWS Locus to
Chromosome 5p13.1
LOCI DISTANCEa
LOD AT v p
Zmax v.00 .05 .10 .20 .30
D5S1964  5.4 4.87 3.35 1.89 5.4 .05
.986
OSMR-CA 8.99 7.59 6.24 3.77 1.86 8.99 .00
1.04
D5S2022 9.86 8.44 7.07 4.56 2.56 9.86 .00
.097
D5S418 10.66b 9.21 7.78 5.06 2.76 10.66 .00
1.07
D5S1457 1.05 3.09 2.81 1.85 .19 3.09 .05
a The distance between loci is given in megabases, according to the
human genome working draft (UCSC Genome Bioinformatics).
b Maximum LOD score.
Figure 1 Clinical and radiological features of patient 3. The gen-
eral appearance is characterized by bowing of the lower limbs, with skin
dimple and camptodactyly. X-rays of the lower limb show bowing of
the long bones, with internal cortical thickening at the concave site and
irregular metaphyses.
1998; Di Rocco et al. 2003), and 9 additional families
(families 2, 3, 9–11, 13, 14, 18, and 19) fulﬁlled the
diagnostic criteria for SWS, namely bowing of the long
bones with ﬂared metaphyses, feeding difﬁculties, respi-
ratory distress, and hyperthermic episodes (ﬁg. 1). Among
the 24 affected children, 16 died in the ﬁrst years of life,
and 8 are still alive (those from families 4, 5, 11, 12, 16,
17, and 19). All survivors presented with a severe bowing
of the long bones, with prominent joints, severe spinal
deformity, and normal mental development.Neurological
symptoms included temperature instability, absent corneal
and patellar reﬂexes, and smooth tongue. Radiological
changes included undertubulation of diaphyses and rare-
faction and striation of metaphyses.
Blood samples were obtained with the written consent
of the patients and unaffected relatives. Genomic DNA
was extracted from leukocytes, according to standard
procedures.
For homozygosity mapping, we used a panel of 400
markers at an average distance of 10 cM.Oligonucleotide
sequences of the OSMR (oncostatin M receptor) CA-re-
peat were: forward 5′-AAG GGT GAT GCC AGT TCA
AG-3′ and reverse 5′-CAC AAA GGC CAT CAC AAC
CT-3′. The MLINK program of the Linkage software
package was used to calculate two-point LOD scores be-
tween the disease phenotype and each of the markers,
under the assumption of a recessive disease with a mutant
allele frequency of 0.01.
A series of 42 intronic primers was designed to amplify
the 20 coding exons of the LIFR gene. Ampliﬁcation
products were puriﬁed and sequenced using the ﬂuores-
cent dideoxy-terminator method on an automatic se-
quencer, ABI 3100. Total RNAs were extracted from hu-
man primary cultured cells (chondrocytes, osteoblasts,
and skin ﬁbroblasts) through use of the RNeasy Mini
Kit (Qiagen GmbH). Complementary DNA was synthe-
sized by priming with random hexamers in the presence
of MuLV reverse transcriptase, according to the manu-
facturer’s protocol (GeneAmpRNAPCRCoreKit, Roche
GmbH). Thirty-ﬁve to 40 PCR cycles were performed at
an annealing temperature of 56C to amplify a 397-bp
fragment speciﬁc for the LIFR gene (forward 5′-CCTCA-
TCTTAGATGTGTCTC-3′; reverse 5′-TTCTCCTCACC-
TGGCATTAC-3′). Sense and antisense primers used for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
ampliﬁcation were as follows: sense, 5′-AGACAGCCG-
CATCTTCTTGT-3′; antisense, 5′-CCACAGTCTTCTG-
AGTGGCA-3′ (587 bp).
For binding experiments, the leukemia inhibitory fac-
tor (LIF) was iodinated using the chloramine T method
(Godard et al. 1992) at a speciﬁc radioactivity of 10,720
counts per minute/fmol. Binding experiments were per-
formed in PBS-BSA. Cells ( /well in 96-well60.3# 10
round-bottom plates) were incubated with increasing
concentrations of labeled LIF in a ﬁnal volume of 50 ml.
Nonspeciﬁc binding was evaluated by including a 100-
fold excess of unlabeled cytokine. Incubation was per-
formed under agitation for 90 min at 4C. Cell-bound
and unbound fractions were separated by centrifugation
through a layer of dibutylphthalate (90%) and parafﬁn
oil (10%). Regression analysis of the binding data was
performed using a one-equilibrium–binding equation.
For western blotting, skin ﬁbroblasts were grown in
Dulbecco’s modiﬁed Eagle medium (with 10% fetal bo-
vine serum). The cells were incubated in a serum-free
medium for 5 min or 30 min with 20 ng/ml LIF (CHEMI-
CON International), were washed twice with PBS, and
were lysed in radioimmunoprecipitation buffer (50 mM
Tris-Cl; pH 7.5; 150mMNaCl; 1%Nonidet P-40; 0.5%
sodium deoxycholate; 1 mM EDTA; 1mg ml1 leupeptin;
300 Am. J. Hum. Genet. 74:298–305, 2004
Figure 2 Map of the region encompassing the candidate genes and genomic organization of LIFR. A, The common region of homozygosity
is located between markers D5S1964 and D5S1457. B, The seven candidate genes identiﬁed in that region. C and D, Exon-intron structure of
the 115-kb LIFR. Mutations were identiﬁed in four extracellular domains.
1mg ml1 aprotinin; 0.2 mM phenylmethylsulfonyl ﬂuo-
ride). Total proteins were quantiﬁed by colorimetric dos-
age; protein extracts were run on NuPAGE 4%–12%
Bis-Tris Gels (Invitrogen) under reducing conditions,were
transferred onto immobilon membranes (Millipore), and
were incubated with anti-STAT 3 and antiphospho-
STAT3 antibodies (Cell Signaling Technology).
For immunocytochemistry, ﬁbroblasts seeded in culture
chambers (FALCON) were stimulated for 15 min with
LIF (20 ng/ml), then were ﬁxed with 4% paraformalde-
hyde, were blocked with 10% sheep serum, and were
incubated with anti-STAT3 antibody (1:200) (Cell Sig-
naling Technology) at room temperature. A ﬂuorescent
dye-conjugated antibody (DAKO) was added for 1 h.
Cells were then examined with a Zeiss LSM 510 con-
focal microscope.
Results
For linkage analysis, 11 families with SWS/SJS2 (10 con-
sanguineous families and 1 nonconsanguineous family)
were included in this study. Using a homozygosity-map-
ping strategy, we found linkage of the disease gene to
chromosome 5p13.1 ( at at locusZ p 10.66 vp 0max
D5S418) (table 1). A recombination event between locus
D5S1964 and the OSMR gene in family 1 deﬁned the
proximal boundary of the genetic interval, and another
recombination event between locus D5S418 and locus
D5S1457 in family 13 deﬁned the distal boundary of the
candidate region (3.2 Mb) (ﬁg. 2A).
A search of the human genome resources of the Na-
tional Center for Biotechnology Information (NCBI) re-
sulted in several putative disease genes within the can-
didate region, including FLJ39155 (similar to perlecan),
disabled-2 (DAB2), complement 9 (C9), Fyn-binding
protein (FYB), oncostatinM receptor (OSMR), andLIFR
(Gearing et al. 1993; ﬁg. 2B). The LIF receptor is a
heterodimer complex composed of the gp190 subunit
referred to as “LIFR” and the gp130 subunit (Gearing
et al. 1991). This receptor is able to bind multiple cy-
tokines, including LIF, OSM, ciliary neurotrophic factor
(CNTF), cardiotrophin 1, and neurotrophin-1/B-cell
stimulating factor 3 (Gearing et al. 1991;Metcalf 2003).
LIFR (gp190) was considered to be a good candidate be-
cause LIFR/ mice present with reduction of fetal bone
volume, with an increased number of osteoclasts, reduc-
tion of astrocyte numbers in spinal cord and brain, and
perinatal death (Ware et al. 1995).
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Figure 3 RT-PCR detection of LIFR transcript and Scatchard
analysis of high-afﬁnity receptor. A, RT-PCR analyses were done using
RNA isolated from control osteoblasts, chondrocytes, and ﬁbroblasts
and from patient ﬁbroblasts (patients 4, 7, and 10). The speciﬁc tran-
script was detected in control osteoblasts, chondrocytes, and ﬁbro-
blasts but was almost absent in SWS ﬁbroblasts. B, Scatchard analysis
showing speciﬁc binding of the iodinated LIF in control ﬁbroblasts
(blackened circles) and the absence of binding in patient 10 ﬁbroblasts
(unblackened circles).
LIFR is composed of 20 exons and encodes a 1,097–
amino acid transmembrane protein, which is composed
of six different domains: two cytokine receptor homology
domains (CRH1 and CRH2), one Ig-like domain (Ig),
one type III ﬁbronectin domain with three modules
(FNIII), one transmembrane domain (TM), and one cyto-
plasmic domain (CD) (ﬁg. 2C) (Gearing et al. 1991; To-
mida and Gotoh 1996; Bitard et al. 2003). A total of 14
distinct mutations was identiﬁed in the 11 initial families
and in eight additional cases (in families 5, 7–10, 12,
14, and 19) (table 2). An identical frameshift insertion
(653_654insT) was identiﬁed in families from the United
Arab Emirates, suggesting a founder effect in that re-
gion. Similarly, the same mutation (R597X) was iden-
tiﬁed in one family from Portugal (family 6), in two
Gypsy families (families 7 and 8), in one French family
(family 9), and in one Swiss family (family 12) (in a
compound heterozygote). It is interesting that 12/14
mutations predicted premature termination of transla-
tion. The mutations were located in CRH1 (3/14), in
CRH2 (2/14), in the Ig-like domain (2/14), or in the
FNIII domains of the protein (7/14) (ﬁg. 2D). The mu-
tations were not identiﬁed in 210 control chromosomes.
RT-PCR analysis of LIFR RNA transcripts detected a
single ampliﬁcation product in osteoblasts, chondrocytes,
and ﬁbroblasts from controls. By contrast, RT-PCR
analysis of the ﬁbroblast RNA transcripts detected ei-
ther no ampliﬁcation product (patient 4) or a weak signal
(patients 7 and 10) (ﬁg. 3A).
Binding experiments on patient and control ﬁbroblasts
through use of iodinated LIF revealed that ﬁbroblasts
frompatients 1, 4, 7, and 10 failed to express high-afﬁnity
LIF receptors, whereas control ﬁbroblasts bound LIF
with an apparent Kd of 0.9 nM and a maximum capacity
of 1,500 sites/cell (ﬁg. 3B). Binding of LIF to the LIFR
complex is known to induce signaling through the JAK/
STAT and MAPK pathways. After phosphorylation by
JAK, STAT3 molecules dimerize and translocate to the
nucleus, where they bind to cytokine-response elements
and ultimately activate gene transcription (Schiemann et
al. 1997; Starr et al. 1997; Dziennis andHabecker 2003).
The activation of STAT3 in response to LIF was tested
in patient and control ﬁbroblasts. Western blot analysis
of ﬁbroblast lysates from patients 1, 4, and 7 with an
antiphospho STAT3 antibody showed that STAT3 failed
to be phosphorylated in response to LIF (5-min stimula-
tion), whereas LIF normally triggered STAT3 phosphory-
lation in control cells (ﬁg. 4A). Similar results were ob-
tained after 30 min (data not shown). Consistently, im-
munoﬂuorescence analysis showed that incubation with
LIF (15 min) triggered nuclear localization of STAT3 in
control ﬁbroblasts, whereas ﬁbroblasts from patient 10
exhibited an exclusive cytoplasmic staining (ﬁg. 4B).
Discussion
We report here the identiﬁcation of null mutations in 19
families with SWS/SJS2. These results ﬁrst conﬁrm that
SWS and SJS2 represent a single entity. The same muta-
tions were identiﬁed in families originating from the
United Arab Emirates, suggesting a founder effect within
that ethnic group. All but two mutations predicted the
generation of a markedly truncated protein. The absence
of any detectable transcript or the marked reduction of
the signal through use of RT-PCR analysis of patient ﬁ-
broblasts suggests that null mutations induced instability
of LIFR transcripts. Moreover, Scatchard and western
blot/immunoﬂuorecence analysis clearly demonstrate that
null LIFR mutations abrogate the LIF-mediated JAK-
STAT3 signaling in SWS.
Cytokines play a major role in bone development and
have a complex and multiphasic effect on osteoblast pro-
liferation and differentiation and on bone formation (Al-
Ta
bl
e
2
LI
FR
M
ut
at
io
ns
Id
en
ti
ﬁ
ed
in
th
e
19
Fa
m
ili
es
w
it
h
SW
S/
SJ
S2
Fa
m
ily
E
th
ni
c
O
ri
gi
n
C
on
sa
ng
ui
ne
ou
s
Pa
re
nt
s
N
o.
of
A
ff
ec
te
d
C
hi
ld
re
n
N
uc
le
ot
id
e
C
ha
ng
e
A
m
in
o
A
ci
d
C
ha
ng
e
M
ut
at
ed
E
xo
n(
s)
Pr
ed
ic
te
d
C
on
se
qu
en
ce
on
th
e
Pr
ot
ei
n
D
om
ai
n
1a
Y
ug
os
la
vi
an
Y
es
2
75
6_
75
7i
ns
T
K
25
3X
7
T
ru
nc
at
ed
Ig
-l
ik
e
2
Se
ne
ga
le
se
Y
es
1
24
34
C
r
T
R
81
2X
17
T
ru
nc
at
ed
FN
II
I
3
Tu
rk
is
h
Y
es
1
22
74
_2
27
5i
ns
T
Y
55
9L
an
d
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
13
co
do
ns
do
w
ns
tr
ea
m
16
T
ru
nc
at
ed
FN
II
I
4a
It
al
ia
n
Y
es
1
16
20
_1
62
1i
ns
A
T
54
1N
an
d
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
7
co
do
ns
do
w
ns
tr
ea
m
12
T
ru
nc
at
ed
FN
II
I
5a
It
al
ia
n
N
o
1
C
17
0d
el
T
57
I
an
d
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
54
co
do
ns
do
w
ns
tr
ea
m
3
T
ru
nc
at
ed
C
R
H
1
6a
G
yp
sy
Y
es
1
17
89
C
r
T
R
59
7X
13
T
ru
nc
at
ed
FN
II
I
7a
G
yp
sy
N
o
1
17
89
C
r
T
R
59
7X
13
T
ru
nc
at
ed
FN
II
I
8a
Po
rt
ug
ue
se
Y
es
1
17
89
C
r
T
R
59
7X
13
T
ru
nc
at
ed
FN
II
I
9
Fr
en
ch
Y
es
1
17
89
C
r
T
R
59
7X
13
T
ru
nc
at
ed
FN
II
I
10
Fr
en
ch
N
o
1
18
9G
r
A
/(
12
93

1G
r
A

11
22
_1
29
1d
el
)
W
63
X
/s
pl
ic
in
g
m
ut
at
io
n
an
d
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
13
co
do
ns
do
w
ns
tr
ea
m
3,
9
T
ru
nc
at
ed
C
R
H
1/
C
R
H
2
11
C
an
ad
ia
n
N
o
1
84
5T
r
C
/1
22
9-
12
32
de
lT
G
A
A
S2
79
P/
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
10
co
do
ns
do
w
ns
tr
ea
m
7,
9
M
is
se
ns
e/
tr
un
ca
te
d
Ig
-l
ik
e/
C
R
H
2
12
a
Sw
is
s
N
o
2
17
89
C
r
T
/2
01
1_
20
12
in
sT
R
59
7X
/f
ra
m
es
hi
ft
ca
us
in
g
a
st
op
,
12
co
do
ns
do
w
ns
tr
ea
m
13
,
14
T
ru
nc
at
ed
FN
II
I
13
Is
ra
el
i
A
ra
b
M
us
lim
Y
es
2
16
01
-1
G
r
A
Sp
lic
in
g
m
ut
at
io
n
12
FN
II
I
14
Is
ra
el
i
A
ra
b
M
us
lim
Y
es
1
24
72
-2
47
6d
el
T
A
T
G
T
S8
24
R
an
d
fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
39
co
do
ns
do
w
ns
tr
ea
m
17
T
ru
nc
at
ed
FN
II
I
15
a
O
m
an
ib
Y
es
2
65
3_
65
4i
ns
T
Fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
2
co
do
ns
do
w
ns
tr
ea
m
6
T
ru
nc
at
ed
C
R
H
1
16
a
Y
em
en
ib
Y
es
1
65
3_
65
4i
ns
T
Fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
2
co
do
ns
do
w
ns
tr
ea
m
6
T
ru
nc
at
ed
C
R
H
1
17
a
Y
em
en
ib
Y
es
2
65
3_
65
4i
ns
T
Fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
2
co
do
ns
do
w
ns
tr
ea
m
6
T
ru
nc
at
ed
C
R
H
1
18
O
m
an
ib
Y
es
1
65
3_
65
4i
ns
T
Fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
2
co
do
ns
do
w
ns
tr
ea
m
6
T
ru
nc
at
ed
C
R
H
1
19
O
m
an
ib
Y
es
1
65
3_
65
4i
ns
T
Fr
am
es
hi
ft
ca
us
in
g
a
st
op
,
2
co
do
ns
do
w
ns
tr
ea
m
6
T
ru
nc
at
ed
C
R
H
1
a
Fa
m
ili
es
1
an
d
8
(C
or
m
ie
r-
D
ai
re
et
al
.
19
98
),
4
an
d
5
(D
i
R
oc
co
et
al
.
20
03
),
6
an
d
7
(C
ha
br
ol
et
al
.
19
97
),
12
(S
up
er
ti
-F
ur
ga
et
al
.
19
98
),
an
d
15
–1
7
(A
l-
G
az
al
i
et
al
.
19
96
,
20
03
)
ha
ve
be
en
re
po
rt
ed
el
se
w
he
re
.
M
ut
at
io
ns
w
er
e
pr
es
en
t
at
th
e
ho
m
oz
yg
ou
s
st
at
e
in
af
fe
ct
ed
ch
ild
re
n
fr
om
fa
m
ili
es
1–
9
an
d
fa
m
ili
es
13
–1
9.
b
Fr
om
U
ni
te
d
A
ra
b
E
m
ir
at
es
.
Dagoneau et al.: LIFR Mutations in SWS/SJS2 303
Figure 4 Analysis of the STAT pathway in control and patient
ﬁbroblasts. A, Patient (patients 1, 4, and 7) and control cell lysates (C1
and C2) analyzed by western blot by use of antiphospho-Tyr STAT3 or
STAT3 antibodies. Fibroblasts were stimulated with LIF (20 ng/ml) for
5 min. Only control cells gave a Phospho-STAT3 signal after LIF stimu-
lation. B, Immunoﬂuorescence of control and patient 10 ﬁbroblastswith
an anti-STAT3 antibody in the absence (upper panel) or presence (lower
panel) of LIF (20 ng/ml) for 15 min. Only LIF-stimulated control cells
showed nuclear localization of the STAT3 protein. Bar p 20mm.
lan et al. 1990; Liu et al. 2002; Metcalf 2003). It is in-
teresting to note, especially since osteoblasts secrete LIF
and express LIFR, that femoral metaphyses of patients
with SWS display irregularities of the chondro-osseous
junction, with rare, thick, and irregular bone trabeculae
and the presence of many osteoclasts (Cormier-Daire et
al. 1998). Consistently, the LIFR/mice show decreased
bone density, especially in the primary spongiosa, with
a reduced number of bone spicules and few well-formed
trabeculae. A sixfold increase in osteoclast numbers was
also observed. By contrast, the developing cartilage bone
appeared normal both inLIFR/mice (Ware et al. 1995)
and in patients with SWS (Cormier-Daire et al. 1998),
even though detectable amounts of LIFR were identiﬁed
in control human chondrocytes (ﬁg. 3). These observa-
tions in both humans and mice suggest that the alteration
of LIFR has a direct effect on osteoblast differentiation
and/or function and, presumably, also on osteoclast
activity, leading to a decrease in bone formation and
mineralization.
Unlike LIFR/ mice, which died perinatally, some
patients with SWS survive and present with dysauto-
nomia symptoms. Some features are reminiscent of the
Schwartz-Jampel syndrome type I, a chondrodystrophic
myotonia, which is caused by mutations in the gene en-
coding perlecan, a component of the neuromuscular
junction (Nicole et al. 2000). More recently, cold-in-
duced sweating syndrome has been ascribed to muta-
tions in theCRLF1 (cytokine receptor like factor 1) gene
also called “CNTF II” (Lesser and Lo 2000; Knappskog
et al. 2003). Both CNTF and LIF are neurotrophic cy-
tokines, involved in the development of the mammalian
nervous system, with profound effects on the survival
and maintenance of motor neurons in brain stem and
spinal cord (Li et al. 1995; Schweizer et al. 2002). CNTF
and LIF stimulate cholinergic differentiation in sym-
pathetic neurons, induce choline acetyltransferase gene
expression, and promote the survival of cholinergic neu-
rons in vitro and in vivo (Dziennis and Habeker 2003).
One can hypothesize, therefore, that the manifestations
of dysautonomia in SWS can be ascribed to impairment
of STAT3 signaling, which is responsible for induction
of the cholinergic and peptidic properties of sympathetic
neurons.
Conversely, the IL-6 type cytokines also play important
roles in the immune system during hematopoiesis and in-
ﬂammation, heart development, adipocyte lipid trans-
port, and reproduction, which were not altered in SWS.
This feature can be explained by function redundancies—
that is, the shared use of the receptor subunit gp130.
Whereas IL-6 and IL-11 induce homodimerization of
gp130, the other IL-6 type cytokines lead to hetero-
dimerization of gp130 with the LIF receptor (Starr et
al. 1997; Metcalf 2003). Apart from exerting these re-
dundant effects, each cytokine is additionally endowed
with speciﬁc functions. The restricted pattern of cyto-
kine expression and the differential signaling abilities in
a cell-type speciﬁc manner may explain cytokine-speciﬁc
effects.
In conclusion, our study shows that SWS and SJS2 are
a single genetic entity and are due to null mutations in
LIFR. The study emphasizes the speciﬁc function of LIFR
in bone remodeling and in the autonomous nervous sys-
tem. We hope that identifying the involvement of LIFR
in a disorder of the autonomous nervous systemwill shed
light on the hitherto poorly understood mechanisms of
dysautonomia in humans, particularly in constitutional,
autoimmune, and neurodegenerative disorders.
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